HMGB1 and neoplasm: In a toll-like receptor 2 (TLR2) [53, 54] or toll-like receptor 4 (TLR4) [54–56]-dependent manner, HMGB1 is abnormally released into the tumor microenvironment (TME) and activates an inflammatory response that promotes tumor progression.